Three Treatments for EGFR-Mutant Non-Small-Cell Lung Cancer with Brain Metastases

被引：0
|
作者：
Fan, Y. [1 ]
Yu, X. [2 ]
Wang, H. [2 ]
机构：
[1] Zhejiang Canc Hosp, Chemotherapy, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Canc Hosp, Thorac Oncol, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Epidermal growth factor receptor; Tyrosine kinase inhibitors; brain metastases;
D O I：
10.1016/j.jtho.2017.09.1510
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-069
引用
收藏
页码：S2228 / S2228
页数：1
相关论文
共 50 条
  • [31] The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer
    Zhong, Wen-Zhao
    Zhou, Qing
    Wu, Yi-Long
    ONCOTARGET, 2017, 8 (41) : 71358 - 71370
  • [32] Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
    Gomes, Jessica Ribeiro
    Cruz, Marcelo Rocha S.
    ONCOTARGETS AND THERAPY, 2015, 8 : 1137 - 1142
  • [33] Clinical Value and Optimal Timing of Cranial Local Therapy among EGFR-Mutant Non-small-cell Lung Cancer with Brain Metastases in the Era of Osimertinib
    Yu, F.
    Ni, J.
    Yu, W.
    Fu, X.
    Zhu, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S175 - S175
  • [34] Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases
    Miyawaki, Eriko
    Kenmotsu, Hirotsugu
    Mori, Keita
    Harada, Hideyuki
    Mitsuya, Koichi
    Mamesaya, Nobuaki
    Kawamura, Takahisa
    Kobayashi, Haruki
    Nakashima, Kazuhisa
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Naito, Tateaki
    Murakami, Haruyasu
    Endo, Masahiro
    Nakasu, Yoko
    Gon, Yasuhiro
    Takahashi, Toshiaki
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 104 (03): : 604 - 613
  • [35] Brain Metastases in Non-Small-Cell Lung Cancer
    Dawe, David E.
    Greenspoon, Jeffrey N.
    Ellis, Peter M.
    CLINICAL LUNG CANCER, 2014, 15 (04) : 249 - 257
  • [36] FDG-PET/CT as a Predictor of Outcome in EGFR-Mutant Non-Small-Cell Lung Cancer
    Gold, Kathryn A.
    Erasmus, Jeremy J.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (08) : 1131 - 1132
  • [37] Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer
    Zhang, Hongye
    Wang, Ruiyu
    Wang, Mingxia
    Luo, Judong
    Liu, Changmin
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (02) : 754 - 762
  • [38] EGFR as a Pharmacological Target in EGFR-Mutant Non-Small-Cell Lung Cancer: Where Do We Stand Now?
    Ke, E-E
    Wu, Yi-Long
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2016, 37 (11) : 887 - 903
  • [39] The efficacy and clinical survival outcome of different first-line treatments in EGFR-mutant non-small cell lung cancer with brain metastases.
    Wang, Huijuan
    Xing, Ruyue
    Zhang, Mina
    Zhang, Xiaojuan
    Yang, Jinpo
    Li, Mengmeng
    Ma, Zhiyong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [40] Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study
    Jung, H. A.
    Park, S.
    Lee, S. -H.
    Ahn, J. S.
    Ahn, M. -J.
    Sun, J. -M.
    ESMO OPEN, 2023, 8 (06)
12345